Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 9/20 | 0.59 |
| ▸ | NPC1 | O15118 | 7/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.59 |
| ▸ | TP53 | P04637 | 2/20 | 0.59 |
| ▸ | FADS1 | O60427 | 1/20 | 0.58 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.58 |
| ▸ | POLB | P06746 | 1/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.57 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.57 |
| ▸ | PKM | P14618 | 1/20 | 0.57 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.56 |
| ▸ | GAA | P10253 | 1/20 | 0.56 |
| ▸ | HPGD | P15428 | 1/20 | 0.53 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5464222 | 0.85 | P2RX1 (0.67) | RAB9ANPC1ALDH1A1GAAHPGD | |
| SCHEMBL5462863 | 0.85 | RAB9A (0.59) | RAB9ANPC1SMN1; SMN2TP53POLB | |
| SCHEMBL5463705 | 0.83 | SRC (0.55) | RAB9ANPC1SMN1; SMN2TP53FADS1 | |
| SCHEMBL5462330 | 0.83 | PNLIP (0.62) | RAB9ANPC1SMN1; SMN2TP53POLB | |
| SCHEMBL5468424 | 0.82 | NPC1 (0.56) | RAB9ANPC1SMN1; SMN2TP53POLB | |
| SCHEMBL14363185 | 0.80 | FADS1 (0.67) | RAB9ANPC1SMN1; SMN2TP53FADS1 | |
| SCHEMBL5468746 | 0.80 | MEN1 (0.54) | RAB9ANPC1SMN1; SMN2TP53KMT2A | |
| SCHEMBL5469870 | 0.79 | TMPRSS4 (0.69) | KMT2A | |
| SCHEMBL4270372 | 0.79 | FADS1 (0.81) | RAB9ANPC1TP53FADS1ALDH1A1 | |
| SCHEMBL30771745 | 0.79 | FADS1 (0.81) | RAB9ANPC1TP53FADS1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070276011-A1 | Plasminogen Activator Inhibitor-1 Inhibitor | INSTITUTE OF MEDICINAL MOLECULAR DESIGN. INC. (JP) | 2007-11-29 | — | — | US | disclosed |
| EP-1666469-A1 | PLASMINOGEN ACTIVATOR INHIBITOR-1 INHIBITOR | Institute of Medicinal Molecular Design, Inc. (JP) | 2006-06-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070276011-A1 | Plasminogen Activator Inhibitor-1 Inhibitor | SERPINE1, SERPINC1, SERPINB1 | RAB9A 3765/4885NPC1 3368/4885SMN1; SMN2 2862/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.